Adjuvant dendritic cell-based immunotherapy in melanoma: insights into immune cell dynamics and clinical evidence from a phase II trial

Our findings support the safety and tolerability of DC vaccination as an adjuvant treatment for melanoma, demonstrating significant immune modulation at both the tumor site and peripherally in relapsed and non-relapsed patients. These results highlight the potential of autologous, personalised DC-based therapies and pave the way for the development of innovative immunotherapy combinations in future treatment strategies. Trial registration ClinicalTrials.gov NCT02718391; EudraCT no. 2014-005123-27.

Authors

Institutions

Publication Details

Journal
Journal of Translational Medicine
Published
2025-04-18
DOI
https://doi.org/10.1186/s12967-025-06403-8
Citations
3
Primary Topic
Immunotherapy and Immune Responses
Type
article
Field-Weighted Citation Impact
2.39

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Adjuvant dendritic cell-based immunotherapy in melanoma: insights into immune cell dynamics and clinical evidence from a phase II trial

Valentina Ancarani, Emanuela Scarpi, Francesco Limarzi, Jenny Bulgarelli et al.
3 citations
Journal of Translational Medicine
Immunotherapy and Immune Responses
2.39
article

Adjuvant dendritic cell-based immunotherapy in melanoma: insights into immune cell dynamics and clinical evidence from a phase II trial

Valentina Ancarani, Emanuela Scarpi, Francesco Limarzi, Jenny Bulgarelli, Massimo Guidoboni, Francesca Tauceri, Francesco De Rosa, Silvia Carloni, Elena Pancisi, Livia Turci, L. Renzi, Laura Capelli, Giovanni Foschi, Marcella Tazzari, Laura Ridolfi, Pietro Cortesi, S Baravelli, Claudia Piccinini, Massimiliano Petrini, Maria Maddalena Tumedei, Sara Pignatta, Ilaria Bronico, Anna Maria Granato, Massimo Framarini, Diana Fanelli, G. Gentili
article en
3 citations

Abstract

Our findings support the safety and tolerability of DC vaccination as an adjuvant treatment for melanoma, demonstrating significant immune modulation at both the tumor site and peripherally in relapsed and non-relapsed patients. These results highlight the potential of autologous, personalised DC-based therapies and pave the way for the development of innovative immunotherapy combinations in future treatment strategies. Trial registration ClinicalTrials.gov NCT02718391; EudraCT no. 2014-005123-27.

Journal of Translational MedicineVol. 23(1)
University of Ferrara (IT), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT), Ospedale G.B. Morgagni - L.Pierantoni (IT)
Ministero della Salute
Good health and well-being
Openalex Percentile: Top 12%
Immunotherapy and Immune Responses
2.39
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.